Category: 340B

New analysis adds to research questioning whether 340B is working as Congress intended

340B / October 13, 2021 October 13, 2021

As the 340B program has grown over the past decade, there has been increased interest in it and ensuring it works in the best interest of patients. Unfortunately, study after study finds that often isn’t the case. In fact, perverse incentives and a lack of hospital accountability seem to undermine 340B. A new study published …

New analysis adds to research questioning whether 340B is working as Congress intended Read More »

340B hospitals among those that provide lowest levels of community benefit across the country

340B, hospitals / July 27, 2021 July 27, 2021

The 340B program reached $38 billion in sales at the discounted price in 2020. This is a 27% increase over sales in 2019, and the program is now more than four times the size it was in 2014. Unfortunately, despite pharmaceutical manufacturers paying more and more money in 340B discounts, there is no evidence that …

340B hospitals among those that provide lowest levels of community benefit across the country Read More »

Getting the 340B program back on track in 2021

340B, access, hospitals, patients / March 10, 2021 March 10, 2021

As our nation continues to fight a global pandemic, the need for access to affordable and quality health care feels even more pressing. This is especially true for vulnerable patients who have been disproportionately impacted by COVID-19. That’s why it has never been more important for policymakers to ensure federal programs, like the 340B program, …

Getting the 340B program back on track in 2021 Read More »

Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients

340B, 340B Spotlight, hospitals / December 17, 2020 December 17, 2020

The New York Times recently ran a story that paints an inaccurate picture of the 340B program, contract pharmacy participation in the program and the biopharmaceutical industry’s commitment to the program. Today, we’re correcting the record. Fact: Manufacturers are still giving the 340B discounts, as required by law, to “covered entities” – more than 12,700 …

Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients Read More »

Key takeaways from new GAO report on covered entities’ lack of compliance with 340B requirements

340B / December 15, 2020 December 15, 2020

In case you missed it, the Government Accountability Office (GAO) released a new report looking at the 340B program and the mechanisms the government has to help ensure compliance with the program’s requirements. This is the latest in series of reports from the government watchdog that has raised concerns with 340B program integrity. Earlier this …

Key takeaways from new GAO report on covered entities’ lack of compliance with 340B requirements Read More »

PhRMA submits comments on ways to refocus the 340B program on America’s vulnerable patients

340B, pharmacy benefit managers / November 2, 2020 November 2, 2020

In response to the Request for Input on Modernizing the 340B Drug Pricing Program issued by Representative Greg Walden and Senator Lamar Alexander, PhRMA has outlined a number of commonsense ways policymakers can get the 340B program back on track and refocused on patients.

340B hospitals and for-profit pharmacies generating significant revenue from program meant to help needy patients

340B, 340B Spotlight, hospitals / October 23, 2020 October 23, 2020

The 340B program – a safety-net federal drug program meant to help vulnerable Americans – has become dominated by many large hospitals and for-profit corporations with no clear evidence they are always helping needy patients. At a time when too many Americans struggle to access the medicines and care they need, it is alarming to …

340B hospitals and for-profit pharmacies generating significant revenue from program meant to help needy patients Read More »

Growth in 340B program has not translated to improvements for patients

340B, 340B Spotlight / October 5, 2020 October 5, 2020

Is 340B benefiting the vulnerable, uninsured patients it was designed to help? That’s the most important question policymakers should be asking in any discussion about the 340B program. Unfortunately, this program is essentially a black box with lax reporting requirements and weak oversight – which means there is little to no clear evidence that patients …

Growth in 340B program has not translated to improvements for patients Read More »